Nicanor Tercero Obaldia Rodriguez
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Vivax | 9 | 2020 | 166 | 3.220 |
Why?
|
| Plasmodium vivax | 8 | 2020 | 202 | 2.730 |
Why?
|
| Aotidae | 13 | 2020 | 59 | 2.480 |
Why?
|
| Antimalarials | 16 | 2020 | 907 | 2.280 |
Why?
|
| Plasmodium falciparum | 20 | 2020 | 1742 | 1.540 |
Why?
|
| Malaria, Falciparum | 16 | 2020 | 1077 | 1.490 |
Why?
|
| Chloroquine | 4 | 2018 | 274 | 1.180 |
Why?
|
| Drug Resistance | 8 | 2018 | 1596 | 0.920 |
Why?
|
| Panama | 10 | 2020 | 28 | 0.820 |
Why?
|
| Artemisinins | 3 | 2016 | 218 | 0.800 |
Why?
|
| Disease Outbreaks | 5 | 2018 | 1749 | 0.770 |
Why?
|
| Vaccines, DNA | 7 | 2017 | 286 | 0.700 |
Why?
|
| Malaria Vaccines | 6 | 2017 | 165 | 0.680 |
Why?
|
| Protozoan Proteins | 9 | 2018 | 847 | 0.660 |
Why?
|
| Monkey Diseases | 1 | 2018 | 71 | 0.610 |
Why?
|
| Haplorhini | 2 | 2018 | 525 | 0.600 |
Why?
|
| Merozoite Surface Protein 1 | 2 | 2017 | 38 | 0.580 |
Why?
|
| Antigens, Protozoan | 5 | 2017 | 316 | 0.550 |
Why?
|
| Genetics, Population | 1 | 2020 | 937 | 0.510 |
Why?
|
| Adaptation, Biological | 1 | 2016 | 147 | 0.490 |
Why?
|
| Travel | 1 | 2020 | 796 | 0.480 |
Why?
|
| Methylene Blue | 1 | 2014 | 155 | 0.460 |
Why?
|
| Parasitemia | 7 | 2017 | 165 | 0.450 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 1667 | 0.440 |
Why?
|
| Leukocytes | 1 | 2020 | 2026 | 0.400 |
Why?
|
| Malaria | 5 | 2020 | 1227 | 0.390 |
Why?
|
| Aotus trivirgatus | 10 | 2009 | 36 | 0.390 |
Why?
|
| Animal Husbandry | 1 | 2011 | 64 | 0.380 |
Why?
|
| Swine Diseases | 2 | 2005 | 61 | 0.340 |
Why?
|
| Bone Marrow | 1 | 2018 | 2911 | 0.300 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 1459 | 0.280 |
Why?
|
| Colombia | 2 | 2020 | 282 | 0.280 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2018 | 1914 | 0.280 |
Why?
|
| Reproduction | 1 | 2011 | 645 | 0.270 |
Why?
|
| Pseudorabies | 1 | 2005 | 6 | 0.250 |
Why?
|
| Tuberculosis | 1 | 2018 | 2017 | 0.250 |
Why?
|
| Parasitic Sensitivity Tests | 2 | 2016 | 89 | 0.210 |
Why?
|
| Animals | 33 | 2020 | 168467 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2017 | 7858 | 0.180 |
Why?
|
| Filtration | 1 | 2020 | 228 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2018 | 3810 | 0.170 |
Why?
|
| Mefloquine | 3 | 2009 | 55 | 0.170 |
Why?
|
| Anopheles | 2 | 2020 | 192 | 0.160 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 18253 | 0.160 |
Why?
|
| Antibodies, Bacterial | 2 | 2018 | 1469 | 0.160 |
Why?
|
| Plasmodium berghei | 4 | 2014 | 159 | 0.160 |
Why?
|
| Papua New Guinea | 1 | 2018 | 46 | 0.160 |
Why?
|
| Antibodies, Protozoan | 4 | 2017 | 252 | 0.160 |
Why?
|
| Tuberculin Test | 1 | 2018 | 206 | 0.150 |
Why?
|
| Saimiri | 1 | 2018 | 334 | 0.140 |
Why?
|
| Aminoquinolines | 1 | 1997 | 107 | 0.140 |
Why?
|
| Metagenomics | 1 | 2020 | 467 | 0.140 |
Why?
|
| Anemia | 3 | 2017 | 1509 | 0.130 |
Why?
|
| Primates | 2 | 2016 | 523 | 0.130 |
Why?
|
| Plasmodium cynomolgi | 1 | 2014 | 3 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2014 | 6312 | 0.120 |
Why?
|
| DNA, Bacterial | 2 | 2018 | 1479 | 0.110 |
Why?
|
| Random Allocation | 1 | 2018 | 2395 | 0.110 |
Why?
|
| Female | 23 | 2020 | 392686 | 0.110 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2014 | 132 | 0.110 |
Why?
|
| Cattle | 1 | 2018 | 3849 | 0.100 |
Why?
|
| Male | 21 | 2020 | 360842 | 0.100 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2011 | 28 | 0.100 |
Why?
|
| Parvoviridae Infections | 1 | 1991 | 36 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1787 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 1334 | 0.090 |
Why?
|
| Housing | 1 | 2015 | 670 | 0.090 |
Why?
|
| Interferon-gamma | 1 | 2018 | 3162 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2011 | 338 | 0.080 |
Why?
|
| Klebsiella Infections | 1 | 1991 | 146 | 0.080 |
Why?
|
| Newcastle Disease | 1 | 1989 | 6 | 0.080 |
Why?
|
| Incidence | 2 | 2020 | 21355 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2016 | 2644 | 0.080 |
Why?
|
| Fetal Death | 1 | 1991 | 435 | 0.080 |
Why?
|
| Choroiditis | 1 | 1989 | 12 | 0.080 |
Why?
|
| Population Dynamics | 1 | 2011 | 307 | 0.080 |
Why?
|
| Amodiaquine | 1 | 2009 | 58 | 0.080 |
Why?
|
| Lipids | 1 | 2020 | 3341 | 0.080 |
Why?
|
| Klebsiella pneumoniae | 1 | 1991 | 250 | 0.080 |
Why?
|
| Thailand | 1 | 2009 | 287 | 0.080 |
Why?
|
| Drug Resistance, Multiple | 1 | 2009 | 255 | 0.080 |
Why?
|
| Haplotypes | 1 | 2014 | 2713 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2014 | 2329 | 0.070 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 2116 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2014 | 2707 | 0.070 |
Why?
|
| Chickens | 1 | 1989 | 859 | 0.070 |
Why?
|
| Optic Neuritis | 1 | 1989 | 174 | 0.070 |
Why?
|
| Adenosine | 1 | 2011 | 808 | 0.070 |
Why?
|
| Plasmodium | 1 | 2008 | 246 | 0.060 |
Why?
|
| Uveitis | 1 | 1989 | 395 | 0.060 |
Why?
|
| Genetic Loci | 1 | 2014 | 2632 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2005 | 397 | 0.060 |
Why?
|
| Sus scrofa | 1 | 2005 | 428 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 8181 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 774 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2017 | 64684 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2015 | 42230 | 0.050 |
Why?
|
| Erythrocytes | 4 | 2011 | 2413 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 1301 | 0.050 |
Why?
|
| DNA, Protozoan | 4 | 2008 | 228 | 0.050 |
Why?
|
| Mass Screening | 1 | 2018 | 5428 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7827 | 0.050 |
Why?
|
| Cause of Death | 1 | 2011 | 3683 | 0.040 |
Why?
|
| Carrier Proteins | 3 | 2002 | 4937 | 0.040 |
Why?
|
| Pyrroles | 1 | 2005 | 1125 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 1182 | 0.040 |
Why?
|
| Quinazolines | 1 | 2005 | 1371 | 0.040 |
Why?
|
| Humans | 12 | 2020 | 761572 | 0.040 |
Why?
|
| Rats | 1 | 2014 | 23741 | 0.040 |
Why?
|
| Young Adult | 2 | 2015 | 59255 | 0.040 |
Why?
|
| Phenotype | 1 | 2016 | 16592 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3713 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 26127 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22176 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 1998 | 178 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 2 | 1999 | 1036 | 0.030 |
Why?
|
| Child | 2 | 2015 | 80156 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 88324 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 1999 | 582 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 1991 | 988 | 0.030 |
Why?
|
| Reticulocytes | 1 | 2016 | 289 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 15936 | 0.030 |
Why?
|
| CpG Islands | 1 | 1999 | 1230 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 26198 | 0.030 |
Why?
|
| Culture Media | 1 | 2016 | 897 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 36192 | 0.030 |
Why?
|
| Parvoviridae | 1 | 1991 | 7 | 0.020 |
Why?
|
| Aged | 2 | 2015 | 169310 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2008 | 3076 | 0.020 |
Why?
|
| Time Factors | 3 | 2009 | 39970 | 0.020 |
Why?
|
| Animals, Laboratory | 1 | 1991 | 46 | 0.020 |
Why?
|
| Adult | 3 | 2015 | 221203 | 0.020 |
Why?
|
| Polyamines | 1 | 2011 | 133 | 0.020 |
Why?
|
| Animals, Wild | 1 | 1991 | 78 | 0.020 |
Why?
|
| Middle Aged | 2 | 2015 | 220920 | 0.020 |
Why?
|
| Newcastle disease virus | 1 | 1989 | 21 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2001 | 427 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 58986 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 15843 | 0.020 |
Why?
|
| Purines | 1 | 2011 | 607 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2008 | 364 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 74213 | 0.020 |
Why?
|
| Peptides | 1 | 1999 | 4358 | 0.020 |
Why?
|
| Immunization | 2 | 2002 | 1227 | 0.020 |
Why?
|
| Death | 1 | 1991 | 676 | 0.020 |
Why?
|
| Plasmids | 2 | 2002 | 2269 | 0.020 |
Why?
|
| Injections, Intramuscular | 2 | 1998 | 554 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 465 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 481 | 0.020 |
Why?
|
| Eye | 1 | 1989 | 712 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2006 | 1085 | 0.020 |
Why?
|
| Mutation | 2 | 2008 | 30054 | 0.010 |
Why?
|
| Solubility | 1 | 2006 | 1091 | 0.010 |
Why?
|
| Feces | 1 | 1991 | 1497 | 0.010 |
Why?
|
| Pregnancy | 3 | 2008 | 29876 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 2005 | 469 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1835 | 0.010 |
Why?
|
| Parasite Egg Count | 1 | 2002 | 29 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 1880 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 2496 | 0.010 |
Why?
|
| Prevalence | 2 | 2005 | 15732 | 0.010 |
Why?
|
| Swine | 1 | 1991 | 5915 | 0.010 |
Why?
|
| Thiazoles | 1 | 2008 | 1517 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 227 | 0.010 |
Why?
|
| Immunity, Active | 1 | 2000 | 58 | 0.010 |
Why?
|
| Mice | 5 | 2008 | 81533 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 1971 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 1130 | 0.010 |
Why?
|
| Vaccination | 1 | 1991 | 3384 | 0.010 |
Why?
|
| Hematocrit | 1 | 2000 | 623 | 0.010 |
Why?
|
| Brain | 1 | 2005 | 27120 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1998 | 116 | 0.010 |
Why?
|
| Immunotherapy, Active | 1 | 1998 | 59 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1999 | 1302 | 0.010 |
Why?
|
| Splenectomy | 1 | 1999 | 391 | 0.010 |
Why?
|
| Hepatitis B Antibodies | 1 | 1998 | 155 | 0.010 |
Why?
|
| Health Policy | 1 | 2008 | 2684 | 0.010 |
Why?
|
| Models, Biological | 1 | 2011 | 9469 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 4772 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1998 | 528 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 5035 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 12990 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 6241 | 0.010 |
Why?
|
| Lung | 1 | 1991 | 10002 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12441 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 6075 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 4853 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 10766 | 0.000 |
Why?
|
| Protein Binding | 1 | 2001 | 9353 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 13446 | 0.000 |
Why?
|
| Neurons | 1 | 2006 | 9463 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 17635 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1998 | 4217 | 0.000 |
Why?
|